United States · Platforms & data · MarketBeat

Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, Citigroup Analyst Says

Published by MarketBeat · United States 33 min ago

Image from MarketBeat Media, LLC. · MarketBeat

Detailed summary

Citigroup increased their price objective on Mirum Pharmaceuticals from $184.00 to $194.00 and gave the stock a "buy" rating in a research note on Wednesday.

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

Seeking Alpha

Solid but narrow footing: UBS sees 3.5% global growth driven by AI capex

CNBC

Prediction markets tied to clinical trials and drug approvals draw lawmakers' ire

Investing.com

Northrop Grumman at Baird conference sees durable demand, growth

MarketWatch

Need money for a down payment? More employers are offering to help.

Yahoo Finance

Crypto-Style Perpetual Futures Will Soon Be Available For Individual Stocks. Here's What Investors Need to Know.

TheStreet